BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

BioXcel Therapeutics

NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second-quarter 2024 financial results on Tuesday, August 6, 2024, before the open of U.S. financial markets. The Company’s management team will also host a conference call and webcast at 8:00 a.m. ET that day to discuss these results and provide a general business update.

The webcast link will be accessible under “News/Events” on the Investors & Media page of the Company’s website at bioxceltherapeutics.com.

*Available for 90 days after the live event

About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on developing medicines in immuno-oncology. The company’s drug re-innovation approach leverages existing approved medicines and/or clinically validated product candidates, coupled with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, visit bioxceltherapeutics.com.

Forward-looking statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend that such forward-looking statements be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release, other than statements of historical fact, should be considered forward-looking statements, including, without limitation, the date and time of the release of the Company’s second quarter 2024 financial results and the related conference call. When used herein, words such as “anticipate,” “believe,” “may,” “continue,” “could,” “projected,” “estimate,” “expect,” “forecast,” “objective,” “intend,” “may,” “could,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based on the Company’s current expectations and various assumptions. The Company believes that there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not achieve its expectations, and its beliefs may not prove to be correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, which can be accessed on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at www.bioxceltherapeutics.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

The story continues

Contact information

Corporate

BioXcel Therapeutics
Erik Kopp
1.203.494.7062
ekopp@bioxceltherapeutics.com

media

Russian Partners
David Schull
1.858-717-2310
David.schull@russopartnersllc.com

Scott Stachowiak
1.646-942-5630
Scott.stachowiak@russopartnersllc.com

Source: BioXcel Therapeutics, Inc.

Fuente